GENFIT (XUP.DE) Stock Price & Overview
FRA:XUP • FR0004163111
Current stock price
The current stock price of XUP.DE is 9.36 EUR. Today XUP.DE is up by 10.12%.
XUP.DE Key Statistics
- Market Cap
- 468.027M
- P/E
- N/A
- Fwd P/E
- 917.65
- EPS (TTM)
- -0.70
- Dividend Yield
- N/A
XUP.DE Stock Performance
XUP.DE Stock Chart
XUP.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to XUP.DE.
XUP.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XUP.DE. XUP.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XUP.DE Earnings
On November 20, 2025 XUP.DE reported an EPS of -0.2 and a revenue of 33.49M. The company missed EPS expectations (-119.13% surprise) and missed revenue expectations (-66.69% surprise).
XUP.DE Forecast & Estimates
12 analysts have analysed XUP.DE and the average price target is 9.17 EUR. This implies a price decrease of -2.06% is expected in the next year compared to the current price of 9.36.
For the next year, analysts expect an EPS growth of -213.72% and a revenue growth -28.5% for XUP.DE
XUP.DE Groups
Sector & Classification
XUP.DE Financial Highlights
Over the last trailing twelve months XUP.DE reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -289.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.98% | ||
| ROE | -74.24% | ||
| Debt/Equity | 0.1 |
XUP.DE Ownership
XUP.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.25 | 37.984B | ||
| 1AE | ARGENX SE | 25.18 | 37.885B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.924B | ||
| 2X1 | ABIVAX SA | N/A | 8.018B | ||
| ABVX | ABIVAX SA | N/A | 8.002B | ||
| GXE | GALAPAGOS NV | N/A | 1.824B | ||
| GLPG | GALAPAGOS NV | N/A | 1.82B | ||
| NANO | NANOBIOTIX | N/A | 1.396B | ||
| 6IV | INVENTIVA SA | N/A | 1.087B | ||
| IVA | INVENTIVA SA | N/A | 1.067B | ||
| PHIL | PHILOGEN SPA | 18.09 | 660.824M | ||
| GNFT | GENFIT | 832.35 | 424.525M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About XUP.DE
Company Profile
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Company Info
IPO: 2006-12-19
GENFIT
Parc Eurasante 885 avenue Eugene Avinee
LOOS HAUTS-DE-FRANCE FR
Employees: 169
Phone: 33320164000
GENFIT / XUP.DE FAQ
What does XUP do?
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
What is the stock price of GENFIT today?
The current stock price of XUP.DE is 9.36 EUR. The price increased by 10.12% in the last trading session.
Does GENFIT pay dividends?
XUP.DE does not pay a dividend.
What is the ChartMill rating of GENFIT stock?
XUP.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is GENFIT (XUP.DE) stock traded?
XUP.DE stock is listed on the Frankfurt Stock Exchange exchange.
What do analysts say about GENFIT (XUP.DE) stock?
12 analysts have analysed XUP.DE and the average price target is 9.17 EUR. This implies a price decrease of -2.06% is expected in the next year compared to the current price of 9.36.
What is the GICS sector and industry of XUP stock?
GENFIT (XUP.DE) operates in the Health Care sector and the Biotechnology industry.